Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...

Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...

As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%. This legal setback for Regeneron comes amid competitive pressures in the ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Here's the rundown. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer. The Eylea ...